Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

508 results about "Central nervous system" patented technology

The central nervous system (CNS) is the part of the nervous system consisting of the brain and spinal cord. The CNS is so named because it integrates the received information and coordinates and influences the activity of all parts of the bodies of bilaterally symmetric animals—that is, all multicellular animals except sponges and [[radiata|radially symmetric animals ] such as jellyfish—and it contains the majority of the nervous system. Many consider the retina and the optic nerve (cranial nerve II), as well as the olfactory nerves (cranial nerve I) and olfactory epithelium as parts of the CNS, synapsing directly on brain tissue without intermediate ganglia. As such, the olfactory epithelium is the only central nervous tissue in direct contact with the environment, which opens up for therapeutic treatments. The CNS is contained within the dorsal body cavity, with the brain housed in the cranial cavity and the spinal cord in the spinal canal. In vertebrates, the brain is protected by the skull, while the spinal cord is protected by the vertebrae. The brain and spinal cord are both enclosed in the meninges. Within the CNS, the interneuronal space is filled with a large amount of supporting non-nervous cells called neuroglial cells.

Pyridopyrimidine derivative as KRAS g12c inhibitor for the treatment of brain metastasis

The present disclosure relates generally to methods for treating or preventing central nervous system (CNS) metastases with a KRAS inhibitor, and more specifically to treating CNS metastases with a pyridopyrimidine derivative.
Owner:FRONTIER MEDICINES CORP

Diagnostic and treatment monitoring based on blood-brain barrier disruption

The disclosure provides technologies that permit detection and / or characterization of brain biomarkers (e.g., disease-associated biomarkers) in non-CNS samples, including by liquid biopsy (e.g., blood, serum, etc.). Among other things, the present disclosure demonstrates that ultrasound opening of the blood brain barrier can achieve detectable increases in brain-derived materials (e.g., brain-derived proteins, neuron-derived extracellular vesicles, and / or cell-free DNA) in readily-sampled systemic liquids.
Owner:INSIGHTEC

Advantageous benzofuran compositions for mental disorders or enhancement

Pharmaceutically active benzofuran compositions for the treatment of mental disorders or for mental enhancement, including for entactogenic therapy. The present invention also includes benzofuran compounds, compositions, and methods for generally modulating central nervous system activity and treating central nervous system disorders.
Owner:TACTOGEN INC

Double-encapsulated lipid nanoparticles entering brain through nose as well as preparation method and application of double-encapsulated lipid nanoparticles

PendingCN120617545ANervous disorderKetone active ingredientsOlfactory Epithelial CellDrug encapsulation
The invention relates to double-encapsulated lipid nanoparticles entering brain through nose and a preparation method and application thereof, the double-encapsulated lipid nanoparticles comprise lipid nanoparticles, drugs in the lipid nanoparticles and rana odorata lectin coupled to the surfaces of the lipid nanoparticles, and the drugs comprise hydrophilic drugs and hydrophobic drugs. According to the invention, the rana odorata lectin and the lipid nanoparticles are coupled, and the rana odorata lectin can be specifically combined with L-fucose residues expressed by olfactory epithelial cells, so that the adhesion of the lipid nanoparticles to olfactory epithelium during nasal administration is enhanced, and the brain entering efficiency of the lipid nanoparticles is finally improved. After entering the brain, the lipid nanoparticles respond to diseased regions with high active oxygen content so as to release drugs. In addition, double-drug encapsulation can target different pathogenesis of central nervous system diseases, and the limitation that a traditional treatment drug is single in action target is improved.
Owner:CHINA NAT TOBACCO QUALITY SUPERVISION & TEST CENT

Pharmaceutical composition containing anisodine or salt thereof and 2-borneol

The invention discloses a pharmaceutical composition which comprises anisodine or salt thereof and 2-borneol or related substances thereof. The pharmaceutical composition provided by the invention has a synergistic effect in treatment of cardia-cerebrovascular diseases, especially central nervous diseases such as acute ischemic stroke, can effectively improve the effect of patients with cerebrovascular diseases, especially central diseases such as acute ischemic stroke, and improves the quality of life.
Owner:NANJING ZHIHE MEDICINE TECH CO LTD

Rehabilitation evaluation system for central nervous system dysfunction patient

A rehabilitation evaluation system for a patient with central nervous system dysfunction comprises the following steps of S1, collecting videos, motion data and pressure data of a user through a data collection layer, S2, uploading the video data to an edge computing server, performing preliminary posture estimation, and S3, performing rehabilitation evaluation. The method comprises the following steps: S1, carrying out edge calculation on the data, S3, transmitting the data subjected to edge calculation to a cloud server for deep modeling analysis of gait and balance parameters, S4, carrying out abnormal mode identification and comparison after parameter analysis, S5, uploading the analyzed data after comparison to a decision application layer, S6, transmitting each parameter and a corresponding processing scheme to a doctor end for a doctor to check, and S5, carrying out data processing. The method has the advantages that through full-link innovation of multi-mode lightweight acquisition, edge cloud hierarchical processing, double-model intelligent diagnosis, reinforcement learning dynamic optimization and visual remote decision, central nervous rehabilitation evaluation extends to a daily life scene from a laboratory, and core breakthrough of precision improvement, efficiency multiplication and personalized enhancement is achieved.
Owner:CENTRAL INTEGRATED MEDICAL MANAGEMENT (NANJING) CO LTD

(R)-3-(3-chloro-5-fluoro-2-((4-(1h-pyrazol-1-yl)-2-methylquinolin-8-yloxy)methyl)phenyl)morpholine derivatives and related compounds as bradykinin (BK) B2 receptor antagonist for treating skin diseases

The invention relates to a compound according to general formula (I), which acts as a bradykinin (BK) B2 receptor antagonist; to a pharmaceutical composition containing one or more of the compound(s) of the invention; to a combination preparation containing at least one compound of the invention and at least one further active pharmaceutical ingredient; and to said compound(s) for use as in a method of treating a skin disorder; eye disease; ear disease; mouth, throat and respiratory disease; gastrointestinal disease; liver, gallbladder and pancreatic disease; urinary tract and kidney disease; disease of male genitale organs and female genitale organs; disease of the hormone system; metabolic disease; cardiovascular disease; blood disease; lymphatic disease; disorder of the central nervous system; brain disorder; musculoskeletal system disease; allergy disorder; pain; infectious disease; inflammatory disorder; injury; immunology disorder; cancer; hereditary disease; or edema.
Owner:PHARVARIS GMBH

Therapeutic phenethylamine compositions and methods of use

There are disclosed phenethylamine compounds, the use of such compounds in the treatment of diseases associated with a serotonin 5-HT2 receptor, pharmaceutical compositions such as tablet compositions and kits containing the compounds, methods of delivering the compounds in a mist via inhalation, and methods of treating diseases or disorders associated with a serotonin 5-HT2 receptor, such as central nervous system (CNS) disorders or psychological disorders with the disclosed compounds.
Owner:CYBIN IRL LTD

Macrophage-polymer lipid nanoparticle composite drug delivery system, preparation method thereof and application of macrophage-polymer lipid nanoparticle composite drug delivery system in cryptococcus infection resistance

The invention discloses a macrophage-polymer lipid nanoparticle composite drug delivery system, a preparation method thereof and application of the macrophage-polymer lipid nanoparticle composite drug delivery system in cryptococcus infection resistance. According to the drug delivery system, alpha-linolenic acid (ALA), high molecular weight chitosan oligosaccharide (HCOS) and amphotericin B (AmB) are used as raw materials to construct nanoparticles AmB-PLHNs, the nanoparticles are loaded in macrophages through the phagocytosis of the macrophages, and the AmB-PLHNs (at) M1 is constructed. AmB is a common medicine for clinically treating Cn infection, but has the problems of toxic and side effects on kidney and incapability of being transferred into the center. The AmB-PLHNs (at) M1 carries AmB-PLHNs to be transferred into the brain according to the blood-brain barrier penetrating characteristic of M1 type macrophages, and the brain entering efficiency of the medicine is improved. By combining the phagocytosis of macrophages on cryptococcus, the inflammation immune regulation function of the macrophages and the bacteriostatic action of the drug-loaded nanoparticles, the drug-loaded nano-particles are used for treating Cn central infection, and the toxic and side effects of AmB are reduced.
Owner:THE NAVAL MEDICAL UNIV OF PLA

Double stranded oligonucleotide compositions for RNA interference and methods relating thereto

The present disclosure provides double stranded oligonucleotides, compositions, and methods relating thereto. The present disclosure encompasses the recognition that structural elements of double stranded oligonucleotides, such as base sequence, chemical modifications (e.g., modifications of sugar, base, and / or internucleotidic linkages) or patterns thereof, and / or stereochemistry (e.g., stereochemistry of backbone chiral centers (chiral internucleotidic linkages), and / or patterns thereof, can have significant impact on oligonucleotide properties and activities, e.g., RNA interference (RNAi) activity, Ago2 loading, thermal stability, in vivo stability, delivery to tissues and into cells, etc. The present disclosure also provides methods for treatment of diseases, e.g., hepatic diseases, central nervous system (CNS) diseases, etc., using provided double stranded oligonucleotide compositions, for example, in RNA interference.
Owner:WAVE LIFE SCI LTD

Methods of treating central nervous system disorders comprising administering lumateperone and a nitric oxide donor

ActiveUS12478623B2Organic active ingredientsOrganic chemistryLumateperoneNeurological problems
The disclosure provides methods for the for treatment of psychosis, such as schizophrenia, or depression (such as bipolar depression) and / or anxiety, comprising administering to a patient in need thereof, (i) a 5-HT2A or 5-HT2A / D2 receptor ligand, for example a substituted heterocycle fused gamma-carboline as described herein, in free, pharmaceutically acceptable salt or prodrug form, and (ii) a nitric oxide donor, separately (sequentially or simultaneously), or in combination (e.g., in a fixed dose combination).
Owner:INTRA CELLULAR THERAPIES INC

Cyclic peptides for treatment of central nervous system injury and uses thereof

The invention provides a cyclic peptide used for treating, improving or preventing nervous system injury of mammals or diseases or pains caused by the injury, neurodegenerative diseases, anxiety or epilepsy or used as a neuronal protective agent, a conjugate containing the cyclic peptide, a pharmaceutical composition containing the cyclic peptide or the conjugate and application of the cyclic peptide and the conjugate.
Owner:BIOCELLS BEIJING BIOTECH CO LTD

Phenylpropanoid compound as well as preparation method and application thereof

PendingCN121108101ANervous disorderAntipyreticLycoris radiataChemical compound
The invention relates to a phenylpropanoid compound as well as a preparation method and application thereof, in particular to a phenylpropanoid compound extracted from pleione bulbus pseudobulb as well as a preparation method and application thereof, and belongs to the technical field of medicines. The invention provides a method for preparing 10 new compounds from pleione bulbocodioides pseudobulb as a raw material for the first time, systematically evaluates the anti-neuroinflammation activity of pleione bulbocodioides pseudobulb, and clarifies the application of pleione bulbocodioides pseudobulb in development and treatment of central nervous system diseases. According to the invention, abnormally activated BV-2 microglial cells induced by LPS (Lipopolysaccharide) are adopted, and the NO release amount is taken as an index, so that the effect of the compound 1-10 on inhibiting excessive activation of the microglial cells is preliminarily evaluated. The result shows that the novel compounds 1-10 can inhibit the release of LPS-induced BV-2 microglial cell NO. Therefore, the compound prepared in the invention can be applied to development of drugs for treating central nervous system diseases.
Owner:SHENYANG PHARMA UNIV

RNAi Agents for Inhibiting Expression of Microtubule Associated Protein Tau (MAPT), Compositions Thereof, and Methods of Use

Described are RNAi agents, compositions that include RNAi agents, and methods for inhibition of a microtubule associated protein tau (MAPT) gene. The MAPT RNAi agents and RNAi agent conjugates disclosed herein inhibit the expression of a MAPT gene. The MAPT RNAi agents are conjugated to an antigen binding protein that may enable subcutaneous delivery of the RNAi agents by facilitating crossing of the blood brain barrier (BBB). Pharmaceutical compositions that include one or more MAPT RNAi agents, optionally with one or more additional therapeutics, are also described. Delivery of the described MAPT RNAi agents to central nervous system (CNS) tissue, in vivo, provides for inhibition of MAPT gene expression and a reduction in MAPT activity, which can provide a therapeutic benefit to subjects, including human subjects, for the treatment of various diseases including Alzheimer's disease, Frontotemporal lobar degeneration dementia (FTLD), Progressive supranuclear palsy, and other tauopathies.
Owner:ARROWHEAD PHARMACEUTICALS INC

DTI-based intractable OAB patient brain network analysis method

The invention discloses a DTI-based brain network analysis method for a refractory OAB patient, and relates to a method for applying diffusion tensor imaging (DTI) and graph theory analysis to explore a central nervous regulation mechanism of the refractory OAB patient. 43 cases of refractory OAB patients and 46 cases of matched healthy contrasts are selected for DTI scanning. The method comprises the following steps: evaluating an overactive bladder symptom score table (OABSS), an overactive bladder symptom questionnaire table (OAB-Q), a Hamilton anxiety scale (HAM-A) and a Hamilton depression scale (HAMD) of all subjects, and recording related clinical data. A DTI and graph theory analysis method is adopted to explore the change of global and local topological attributes of the brain structure network of the intractable OAB patient. And further performing brain network function connection analysis on the discovered differential brain region as a seed point.
Owner:WUXI NO 2 PEOPLES HOSPITAL

Methods of treating or controlling cytotoxic cerebral edema

The present invention relates to the use of selective aquaporin inhibitors, e.g., of aquaporin-4 or aquaporin-2, e.g., certain phenylbenzamide compounds, for the prophylaxis, treatment and control of aquaporin-mediated conditions, e.g., diseases of water imbalance, for example edema (particularly edema of the brain and spinal cord, e.g., following trauma or ischemic stroke, as well as the edema associated with glioma, meningitis, acute mountain sickness, epileptic seizures, infections, metabolic disorders, hypoxia, water intoxication, hepatic failure, hepatic encephalopathy, diabetic ketoacidosis, abscess, eclampsia, Creutzfeldt-Jakob disease, and lupus cerebritis, as well as edema consequent to microgravity and / or radiation exposure, as well as edema consequent to invasive central nervous system procedures, e.g., neurosurgery, endovascular clot removal, spinal tap, aneurysm repair, or deep brain stimulation, as well as retinal edema), as well as hyponatremia and excess fluid retention, and diseases such as epilepsy, retinal ischemia and other diseases of the eye associated with abnormalities in intraocular pressure and / or tissue hydration, myocardial ischemia, myocardial ischemia / reperfusion injury, myocardial infarction, myocardial hypoxia, congestive heart failure, sepsis, and neuromyelitis optica, as well as migraines, as well as to novel assays for identifying aquaporin inhibitors.
Owner:AEROMICS INC

Dynamics within supramolecuar IKVAV matrices enhance functional maturation of human IPSCS-derived neurons and regeneration

Provided herein are peptide amphiphiles (PAs) comprising a bioactive peptide, nanofibers displaying the bioactive PAs, and methods of use thereof. The disclosed peptide amphiphiles comprise a hydrophobic tail, a structural peptide segment, a charged peptide segment, and a bioactive IKVAV peptide. The disclosed PAs may be used in cell culture methods and in methods of treating central nervous system injury.
Owner:NORTHWESTERN UNIV

Phenol derivatives and their use in medicine

This invention provides a novel GABA structure with better efficacy, reduced side effects, and greater safety for clinical use. A This invention relates to receptor agonists, specifically a phenol derivative, its preparation method, and its use in the central nervous system. The phenol derivative provided by this invention offers more and better drug options for inducing or maintaining anesthesia in animals or humans, promoting sedation and hypnosis, and treating and / or preventing anxiety, nausea, vomiting, migraines, seizures, epilepsy, neurodegenerative diseases, and other central nervous system-related disorders.
Owner:HINYE PHARM CO LTD

Fc-modified biologics for localized delivery to compartments, particularly the CNS

The present invention relates to a polypeptide comprising the crystallizable fragment (Fc) region of IgG for use in the prevention or treatment of diseases, particularly diseases affecting the central nervous system. The polypeptide is administered locally to the affected compartment, particularly the central nervous system. The Fc region has a modification that reduces affinity for the neonatal Fc receptor (FcRn), resulting in increased brain to serum concentrations of the polypeptide.
Owner:UNIVERSITY OF ZURICH

Exosome nasal delivery preparation as well as preparation method and application thereof

The invention relates to the technical field of exosome preparations, and particularly discloses an exosome nasal delivery preparation as well as a preparation method and application thereof. The preparation comprises the following components: 1 * 10 < 9 >-5 * 10 < 11 > particle number / ml of exosome, 1%-4% w / v of a saccharide protective agent, 0.5%-4.5% w / v of an alcohol protective agent, 0.05%-1% w / v of an absorption enhancer and a solvent. The exosome nasal delivery preparation can break through the blood brain barrier and quickly take effect, and the intracerebral delivery efficiency of the exosome nasal delivery preparation can be improved by 2-5 times compared with intravenous injection. The nasal administration preparation can be used for treating central nervous system diseases such as cerebral apoplexy and the like, and can remarkably improve the neurological function, reduce the cerebral infarction area and promote functional recovery.
Owner:P S K BIOSCIENCE CO LTD

Use of synthetic AAV capsids for gene therapy of muscle and central nervous system disorders

ActiveJP7911520B2MedicineCapsid
The present invention relates to the use of recombinant porcine adeno-associated virus (AAV) vectors comprising peptide-modified porcine AAV serotype 1 (AAVpo1) capsids in the gene therapy of muscle and / or central nervous system (CNS) disorders, particularly neuromuscular diseases such as genetic neuromuscular diseases.
Owner:GENETHON +3

Modulation of the gut microbiome to treat mental disorders or diseases of the central nervous system

The present disclosure relates to methods of treating at least one symptom of a mental disorder or disease of the central nervous system in a subject by modulating the amount of GABA produced in the subject's gut. The present disclosure also relates to methods of culturing the bacterial strain new bacterial strains. Also disclosed are methods of identifying bacterial strains capable of producing GABA, and engineering strains to produce GABA.
Owner:HOLOBIOME INC

Compositions and methods for treating sequelae of hearing loss

Provided are compositions and method for prophylaxis and / or therapy of hearing loss or related dysfunctions, including but not limited to tinnitus, that could be ameliorated by restoring central nervous system inhibitory synapses. The compositions include polynucleotides and viral vectors that are used to express at least one GABA receptor component which may be a GABAA receptor alpha 1 subunit or GABAR receptor Ib subunit. Expression of the GABA receptor may be under control of a CaMKII promoter.
Owner:NEW YORK UNIV

Car-t cell having good blood-brain barrier permeability, product, and use

Provided are a CAR-T cell having good blood-brain barrier permeability, a product, and a use. On the basis of the research on CAR-T cell therapy for central nervous system diseases, provided are a CAR-T cell having good blood-brain barrier permeability and a corresponding drug, for use in treating or relieving central nervous system diseases. Such a CAR-T cell uses a B cell maturation antigen as a target, and highly expresses a CXCR3 chemokine receptor and CCL1, CCL3 and CCL4 chemokines. Also provided is a product for testing and determining the blood-brain barrier permeability of the CAR-T cell, e.g., a probe, a reagent, and a kit, thereby accurately testing and determining the blood-brain barrier permeability of a certain CAR-T cell.
Owner:XIEHE HOSPITAL ATTACHED TO TONGJI MEDICAL COLLEGE HUAZHONG SCI & TECH UNIV